Skip to content

603811.SH

Zhejiang Cheng Yi Pharmaceutical Co., Ltd.

SSE · Healthcare · Medical - Pharmaceuticals · CN

CNY 7.24
−2.16%
Ask drillr

Year over year

Reported trailing growth

Revenue
+10.8%
EBITDA
EBIT
-6.9%
EPS
-6.8%
Free cash flow
+1.5%
Operating cash flow
+10.2%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
+7.4%
EBITDA
+12.1%
EBIT
+11.0%
Net income
+6.5%
EPS
+7.6%
Free cash flow
+37.7%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026